Circulation reports最新文献

{"title":"Transcatheter Strategy for Severe Mitral Regurgitation Requiring Percutaneous Ventricular Assist Device Support.","authors":"Tsuyoshi Isawa, Yusuke Toki, Masataka Taguri, Norio Tada, Shigeru Toyoda","doi":"10.1253/circrep.CR-26-0155","DOIUrl":"10.1253/circrep.CR-26-0155","url":null,"abstract":"<p><strong>Background: </strong>Data on transcatheter strategies in patients with severe mitral regurgitation (MR) and advanced chronic heart failure requiring Impella support remain limited.</p><p><strong>Methods and results: </strong>We retrospectively analyzed 33 patients with severe MR and advanced chronic heart failure requiring Impella support, treated with a transcatheter strategy (n=17) or a conservative strategy (n=16). In an overlapweighted Cox model, the transcatheter strategy was associated with a lower in-hospital mortality rate (hazard ratio, 0.13; 95% confidence interval, 0.03-0.52; P=0.004).</p><p><strong>Conclusions: </strong>A transcatheter strategy had survival benefit for this high-risk population.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 9","pages":"1570-1572"},"PeriodicalIF":2.3,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148932235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracardiac Adipose Tissue Mimicking an Intracavitary Left Atrial Mass on Echocardiography.","authors":"Ayaka Ino, Naoki Fujimoto, Naoki Hashimoto, Suguru Araki, Hiroki Mori, Taku Omori, Emiyo Sugiura, Kaoru Dohi","doi":"10.1253/circrep.CR-26-0235","DOIUrl":"https://doi.org/10.1253/circrep.CR-26-0235","url":null,"abstract":"","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1767-1768"},"PeriodicalIF":2.3,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Native Spleen T1 Mapping for the Assessment of Hepatic Congestion in Children With Congenital Heart Disease.","authors":"Katsuo Tao, Kenichiro Yamamura, Masaki Sato, Koichi Sagawa, Yuichi Ishikawa","doi":"10.1253/circrep.CR-25-0343","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0343","url":null,"abstract":"<p><strong>Background: </strong>Congestive hepatopathy in congenital heart disease (CHD) can lead to portal hypertension. Liver native T1 relaxation time (LT1) was reported to be associated with elevated central venous pressure and liver injury in CHD. This study investigated the utility of spleen native T1 relaxation time (ST1) in children with CHD, particularly those with Fontan circulation, and its association with hemodynamic parameters and biomarkers of liver injury.</p><p><strong>Methods and results: </strong>This study included 120 patients with CHD (biventricular repair, 39; bidirectional Glenn shunt, 31; and Fontan circulation, 50) who underwent blood tests, cardiac catheterization, and cardiac magnetic resonance imaging performed within 48 h. Age-corrected ST1 (cST1; expressed as a percentage of normal) was calculated based on data from 22 control subjects (healthy children: no structural heart disease, normal cardiac function, normal systemic hemodynamics). cST1 was significantly correlated with net inferior vena cava (IVC) flow in both the overall cohort (r=0.364, P<0.001) and Fontan group (r=0.368, P<0.009). Multiple linear regression analysis showed that aspartate aminotransferase (AST) (P=0.011), LT1 (P=0.005), and net IVC flow (P=0.041) remained independent predictors of cST1 in the overall cohort, whereas AST (P<0.001) and non-alcoholic fatty liver disease fibrosis scores (P=0.029) were independent predictors in the Fontan group.</p><p><strong>Conclusions: </strong>Age-corrected ST1 may serve as a non-invasive surrogate marker of systemic venous congestion and hepatic involvement in children with CHD.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1729-1737"},"PeriodicalIF":2.3,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy.","authors":"Kimi Sato, Naoto Kawamatsu, Masayoshi Yamamoto, Tomoko Machino-Ohtsuka, Tatsuhiro Sakamoto, Takeshi Yamada, Yoshiyuki Yamamoto, Masato Homma, Bryan J Mathis, Ikuo Sekine, Tomoko Ishizu","doi":"10.1253/circrep.CR-26-0218","DOIUrl":"https://doi.org/10.1253/circrep.CR-26-0218","url":null,"abstract":"<p><strong>Background: </strong>We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM).</p><p><strong>Methods and results: </strong>We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events.</p><p><strong>Conclusions: </strong>This study failed to demonstrate ponatinib efficacy. Further studies may evaluate the effect of different biochemical targets on PTTM.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1758-1760"},"PeriodicalIF":2.3,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Impact of Interlesion Distance on Acute Pulmonary Vein Isolation Success in Patients With Paroxysmal Atrial Fibrillation.","authors":"Keika Oyama, Yoshihisa Naruse, Yuki Arakawa, Shuhei Kobayashi, Hironori Nakamura, Naruya Ishizue, Jun Kishihara, Hidehira Fukaya, Tomoaki Nagao, Natsuko Hosoya, Kohei Sawasaki, Masahiro Muto, Michitomo Kawahito, Yuki Tokonami, Kazuki Ito, Yutaro Kaneko, Taro Narumi, Makoto Sano, Yuichiro Maekawa","doi":"10.1253/circrep.CR-26-0207","DOIUrl":"https://doi.org/10.1253/circrep.CR-26-0207","url":null,"abstract":"<p><strong>Background: </strong>Achieving pulmonary vein isolation (PVI) through contiguous lesions is important for durable PVI treatment of atrial fibrillation (AF). We hypothesized that the flexible-tip TactiFlex catheter, with its enhanced stability, would allow for successful acute PVI even with an extended interlesion distance (ILD) of 6 mm.</p><p><strong>Methods and results: </strong>The WILD (Wide ILD) PVI trial was a prospective, multicenter, single-blind randomized non-inferiority trial. A total of 94 patients with paroxysmal AF were enrolled and randomly allocated to either a wide ILD group (≤6 mm, n=52) or a standard ILD group (≤4 mm, n=42). The primary endpoint was acute PVI success, defined as first pass isolation without early reconnection. The non-inferiority margin was set at -10.0%. The 6-mm group did not meet the criteria for non-inferiority compared to the 4-mm group (56.7% vs. 68.7%; absolute difference: -11.9% [95% confidence interval: -25.7 to 1.8%]; P for non-inferiority=0.664). Conversely, the 6-mm strategy significantly reduced the total number of RF applications (47±10 vs. 73±17, P=0.001) and total ablation time (528±119 s vs. 825±233 s, P<0.001) compared to the 4-mm group.</p><p><strong>Conclusions: </strong>The 6-mm ILD strategy was inferior to the standard 4-mm strategy for acute PVI success. Despite significant gains in procedural efficiency, maintaining an ILD ≤4 mm is recommended to ensure high acute procedural success when using the TactiFlex catheter.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1749-1757"},"PeriodicalIF":2.3,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Real-World Evidence of Clinical and Echocardiographic Changes After Vutrisiran Initiation in Patients With Variant Transthyretin Amyloid Cardiomyopathy in Non-Endemic Regions: A Single-Center Observational Study.","authors":"Takuto Zaizen, Hidekazu Kondo, Teruaki Masuda, Shotaro Saito, Keisuke Yonezu, Kaori Sumi, Keisuke Sato, Saki Yoshimura, Shuhei Furukawa, Yuki Oba, Yuki Kubota, Yuki Iwabuchi, Tetsuya Uemura, Shuichiro Yamauchi, Nozomi Kodama, Masayuki Takano, Hiroyuki Kodama, Kei Hirota, Miho Miyoshi, Akira Fukui, Tomoko Fukuda, Kaori Ezaki, Hidefumi Akioka, Tetsuji Shinohara, Yasushi Teshima, Noriyuki Kimura, Naohiko Takahashi","doi":"10.1253/circrep.CR-26-0193","DOIUrl":"https://doi.org/10.1253/circrep.CR-26-0193","url":null,"abstract":"<p><strong>Background: </strong>Real-world data describing the clinical course after vutrisiran initiation in patients with variant transthyretin amyloid cardiomyopathy (ATTRv-CM) in non-endemic regions remain limited, particularly in Asian cohorts and in patients transitioning from patisiran. We evaluated preliminary real-world changes after vutrisiran initiation in patients with ATTRv-CM.</p><p><strong>Methods and results: </strong>This single-center retrospective observational study included 18 patients with ATTRv-CM from the Oita-ATTR-CM cohort. Ten patients who initiated small interfering RNA therapy with vutrisiran were classified as the vutrisiran-naive group, and 8 patients who switched from patisiran to vutrisiran were classified as the vutrisiran-switch group. Changes in transthyretin (TTR), N-terminal pro B-type natriuretic peptide (NT-proBNP), troponin T, and echocardiographic parameters from baseline to 1 year were descriptively evaluated. Vutrisiran markedly reduced TTR in both groups. NT-proBNP significantly decreased in both groups, and troponin T decreased only in the vutrisiran-naive group. E/e' significantly decreased in both groups, whereas left ventricular ejection fraction, interventricular septal thickness, and left ventricular mass remained largely unchanged. During follow up, 2 patients were hospitalized for heart failure and 1 died of a non-cardiovascular cause; all events occurred in the vutrisiran-switch group.</p><p><strong>Conclusions: </strong>In this preliminary single-center real-world cohort, vutrisiran use was feasible and was accompanied by sustained TTR suppression and descriptive decreases in NT-proBNP and E/e' over 1 year. These findings should be interpreted as exploratory real-world observations rather than evidence of definitive efficacy.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1696-1703"},"PeriodicalIF":2.3,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149172333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness and Perceived Need for Transitional Care in Childhood-Onset Cardiomyopathy Among Adult Cardiologists: A Nationwide Survey in Japan.","authors":"Katsura Soma, Ryota Ochiai, Ryosuke Minatoya, Mariko Sakka, Hiroyuki Tsutsui, Norihiko Takeda, Atsushi Yao","doi":"10.1253/circrep.CR-26-0110","DOIUrl":"https://doi.org/10.1253/circrep.CR-26-0110","url":null,"abstract":"<p><strong>Background: </strong>Transitional care is essential for patients with childhood-onset chronic diseases to ensure age-appropriate lifelong care. In contrast to congenital heart disease (CHD), for which transition/transfer systems have been relatively well established, childhood-onset cardiomyopathy (ChO-CM) lacks an established transitional care system in Japan. Our previous nationwide survey clarified the pediatric cardiologists' perspective, but awareness of and perceived need for transitional care among adult cardiologists have remained unclear. Therefore, this study investigated adult cardiologists' awareness of and perceived need for transitional care for ChO-CM.</p><p><strong>Methods and results: </strong>A nationwide questionnaire survey was conducted in 1,347 cardiovascular departments in Japan to examine adult cardiologists' awareness of and perceived need for transitional care for ChO-CM. Valid responses were obtained from 332 departments. Among the respondents, 157 (47.3%) were aware of transitional care, whereas 200 (60.2%) answered that transitional care was necessary for all CM cases. Multivariable logistic regression analysis showed that experience in treating hypertrophic cardiomyopathy (HCM) was independently associated with both awareness of transitional care and perceived need for it.</p><p><strong>Conclusions: </strong>Awareness of transitional care for ChO-CM among adult cardiologists in Japan remains limited. However, most respondents recognized the need for transitional care. Clinical experience with HCM may promote recognition of the importance of transitional care. These findings highlight the need to develop structured transition systems for patients with ChO-CM in Japan.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1720-1728"},"PeriodicalIF":2.3,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149172161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Religiosity, Symptoms, and the Quality of End of Life for Cardiovascular Disease Patients.","authors":"Kazuhisa Kaneda, Hiroki Shiomi, Koh Ono, Atsushi Mizuno, Sayaka Funabashi, Takashi Kohno, Yoko Nakazawa, Mitsunori Miyashita, Asao Ogawa","doi":"10.1253/circrep.CR-26-0070","DOIUrl":"https://doi.org/10.1253/circrep.CR-26-0070","url":null,"abstract":"<p><strong>Background: </strong>Religiosity is a well-described core component of palliative care in the end-of-life (EOL) care of cancer patients. However, studies examining associations between religiosity, physical symptoms, quality of care (QOC), and quality of death (QOD) in cardiovascular disease (CVD) patients at EOL are lacking.</p><p><strong>Methods and results: </strong>This nationwide cross-sectional mortality follow-back survey sent a questionnaire to bereaved caregivers of patients who had died of CVD in 2017. Responses to the Memorial Symptom Assessment Scale (MSAS), Care Evaluation Scale (CES), and Good Death Inventory (GDI) were assessed, stratified by the presence of religiosity. Responses regarding religiosity were analyzed for 4,436 of 15,047 questionnaires. In all, 795 (17.9%) caregivers reported the patient was supported by religiosity in the 1 month before death. The group with religiosity was older (mean [±SD] age 88.9±8.7 vs. 86.7±9.4 years; P<0.001), more likely to be female (70.9% vs. 60.3%; P<0.001), less likely to have been hospitalized before death (15.8% vs. 24.0%; P<0.001), reported significantly fewer symptoms on the MSAS, and had better QOC and QOD according to CES and GDI subscores. Total CES and GDI scores were significantly better in the group with than without religiosity (CES: 69.2±21.9 vs. 63.6±24.2, respectively [P<0.001]; GDI: 65.4±17.0 vs. 53.7±22.1, respectively [P<0.001]).</p><p><strong>Conclusions: </strong>Religiosity may contribute to reduced physical symptoms and improved QOC and QOD among CVD patients at EOL.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 10","pages":"1639-1648"},"PeriodicalIF":2.3,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhaled Nitric Oxide Therapy and Changes in Pulmonary Artery Pulsatility Index During Venoarterial Extracorporeal Membrane Oxygenation Weaning in Cardiogenic Shock Requiring ECPELLA.","authors":"Tomoya Ishiguro, Masanobu Yanase, Yohei Kobayashi, Kazuhiro Terashima, Hideto Nisihimura, Hideki Kawai, Yoshiyuki Takami, Tomonobu Abe, Hideo Izawa","doi":"10.1253/circrep.CR-25-0295","DOIUrl":"10.1253/circrep.CR-25-0295","url":null,"abstract":"<p><strong>Background: </strong>Inhaled nitric oxide (iNO) selectively dilates pulmonary vessels and reduces pulmonary vascular resistance, potentially improving right ventricular (RV) function. However, its clinical benefit in patients with cardiogenic shock requiring ECPELLA (i.e., combined Impella® (ABIOMED) and venoarterial extracorporeal membrane oxygenation (VA-ECMO) remains unclear. The aim of this study was to evaluate the impact of iNO on RV function in this critical population.</p><p><strong>Methods and results: </strong>Between September 2017 and June 2023, we retrospectively analyzed 54 consecutive patients with cardiogenic shock treated with ECPELLA. Patients were divided into 2 groups based on the use of iNO. RV function was assessed using the pulmonary artery pulsatility index (PAPi) at the time of ECPELLA initiation (Pre-PAPi) and VA-ECMO weaning (Post-PAPi). The iNO group had a significantly lower Pre-PAPi, prompting propensity-score matching to adjust for baseline differences. After matching, the Post-PAPi was significantly higher in the iNO group than in the non-iNO group (1.95 [1.63-3.00] vs. 1.40 [0.50-2.05], P<0.05). A significant interaction between iNO use and PAPi change was observed (P=0.006), suggesting an iNO-mediated improvement in RV function.</p><p><strong>Conclusions: </strong>In patients with cardiogenic shock requiring ECPELLA support, adjunctive iNO therapy was associated with greater improvement in PAPi at the time of VA-ECMO weaning. These findings suggest a potential role for iNO in optimizing hemodynamics during the transition from ECPELLA to Impella-only support.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 9","pages":"1480-1487"},"PeriodicalIF":2.3,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148932216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhaled Nitric Oxide During ECPELLA Weaning: Interpreting Pulmonary Artery Pulsatility Index Beyond a Single Number.","authors":"Yusuke Motoji","doi":"10.1253/circrep.CR-26-0196","DOIUrl":"10.1253/circrep.CR-26-0196","url":null,"abstract":"","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"8 9","pages":"1488-1489"},"PeriodicalIF":2.3,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148932240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}